

# ASX Release

---

## **SUDA ACHIEVES ISO 9001:2015 ACCREDITATION**

**PERTH, AUSTRALIA – 31 July 2017:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that it has achieved ISO 9001:2015 accreditation. ISO 9001 is the international standard that specifies requirements for a quality management system.

Organisations, such as SUDA, use the ISO 9001 standard to demonstrate their ability to consistently provide products and services that meet customer and regulatory requirements. For SUDA, this includes its development services for pharmaceutical companies seeking to formulate APIs into proprietary oro-mucosal sprays with unique advantages.

SUDA is one of the first Australian pharmaceutical companies to be certified under the more rigorous requirements of the latest version of the quality standard, ISO 9001:2015. This version includes greater emphasis on risk management, leadership involvement and interactions with stakeholders such as shareholders, pharmaceutical partners and regulatory agencies.

SUDA's CEO, Mr Stephen Carter, commented: "We are delighted to have been re-certified under the more extensive ISO 9001:2015 version of the international quality standard. This certification has helped to attract Pfizer Consumer Healthcare and other prospective Pharma partners to work with SUDA in the knowledge that we have a quality management system that meets the highest international standards."



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**  
**SUDA LTD**  
Tel: +61 8 6142 5555  
[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

## **NOTES TO EDITORS:**

### **About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)